Skip to content

Research at St Andrews

University > Research portal > Research publications > In vivo safety assessment of rhodomyrtone, a potent compound...

In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract

Research output: Contribution to journal › Article › peer-review

DOI

Open Access permissions

Open

Links

Standard

In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. / Siriyong, Thanyaluck; Ontong, Julalak Chorachoo; Leejae, Sukanlaya; Suwalak, Sakol; Coote, Peter John; Voravuthikunchai, Supayang Piyawan.

In: Toxicology Reports, Vol. 7, 31.07.2020, p. 919-924.

Research output: Contribution to journal › Article › peer-review

Harvard

Siriyong, T, Ontong, JC, Leejae, S, Suwalak, S, Coote, PJ & Voravuthikunchai, SP 2020, 'In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract', Toxicology Reports, vol. 7, pp. 919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

APA

Siriyong, T., Ontong, J. C., Leejae, S., Suwalak, S., Coote, P. J., & Voravuthikunchai, S. P. (2020). In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. Toxicology Reports, 7, 919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

Vancouver

Siriyong T, Ontong JC, Leejae S, Suwalak S, Coote PJ, Voravuthikunchai SP. In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. Toxicology Reports. 2020 Jul 31;7:919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

Author

Siriyong, Thanyaluck ; Ontong, Julalak Chorachoo ; Leejae, Sukanlaya ; Suwalak, Sakol ; Coote, Peter John ; Voravuthikunchai, Supayang Piyawan. / In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. In: Toxicology Reports. 2020 ; Vol. 7. pp. 919-924.

Bibtex - Download

@article{4ec4fcfd205847378d44ecd6301fbeec,
title = "In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract",
abstract = "BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.",
keywords = "Toxicity, Rhodomyrtone, Invertebrate, Vertebrate",
author = "Thanyaluck Siriyong and Ontong, {Julalak Chorachoo} and Sukanlaya Leejae and Sakol Suwalak and Coote, {Peter John} and Voravuthikunchai, {Supayang Piyawan}",
note = "This research was funded by the Thailand Research Fund Senior Research Scholar (Grant number RTA6180006).",
year = "2020",
month = jul,
day = "31",
doi = "10.1016/j.toxrep.2020.07.013",
language = "English",
volume = "7",
pages = "919--924",
journal = "Toxicology Reports",
issn = "2214-7500",
publisher = "Elsevier Scientific Publishers Ireland",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract

AU - Siriyong, Thanyaluck

AU - Ontong, Julalak Chorachoo

AU - Leejae, Sukanlaya

AU - Suwalak, Sakol

AU - Coote, Peter John

AU - Voravuthikunchai, Supayang Piyawan

N1 - This research was funded by the Thailand Research Fund Senior Research Scholar (Grant number RTA6180006).

PY - 2020/7/31

Y1 - 2020/7/31

N2 - BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.

AB - BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.

KW - Toxicity

KW - Rhodomyrtone

KW - Invertebrate

KW - Vertebrate

U2 - 10.1016/j.toxrep.2020.07.013

DO - 10.1016/j.toxrep.2020.07.013

M3 - Article

VL - 7

SP - 919

EP - 924

JO - Toxicology Reports

JF - Toxicology Reports

SN - 2214-7500

ER -

Related by author

  1. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae.

    DeSarno, A. E., Parcell, B. J. & Coote, P. J., 14 Oct 2020, In: Pathogens and Disease. Advance Article

    Research output: Contribution to journal › Article › peer-review

  2. Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition

    Siriyong, T., Murray, R. M., Bidgood, L. E., Young, S. A., Wright, F., Parcell, B. J., Voravuthikunchai, S. P. & Coote, P. J., 24 Jun 2019, In: Scientific Reports. 9, 13 p., 9098.

    Research output: Contribution to journal › Article › peer-review

  3. Steroidal alkaloids and conessine from the medicinal plant Holarrhena antidysenterica restore antibiotic efficacy in a Galleria mellonella model of multidrug-resistant Pseudomonas aeruginosa infection

    Siriyong, T., Voravuthikunchai, S. P. & Coote, P. J., 19 Oct 2018, In: BMC Complementary and Alternative Medicine. 18, 10 p., 285.

    Research output: Contribution to journal › Article › peer-review

  4. Evaluation of greater wax moth larvae, Galleria mellonella, as a novel in vivo model for non-tuberculosis Mycobacteria infections and antibiotic treatments

    Entwistle, F. & Coote, P. J., 1 Apr 2018, In: Journal of Medical Microbiology. 67, p. 585-597 13 p., 000696.

    Research output: Contribution to journal › Article › peer-review

  5. Effective immunosuppression with dexamethasone phosphate in the Galleria mellonella larva infection model resulting in enhanced virulence of Escherichia coli and Klebsiella pneumoniae

    Perez Torres, M., Entwistle, F. & Coote, P. J., Aug 2016, In: Medical Microbiology and Immunology. 205, 4, p. 333-342 11 p.

    Research output: Contribution to journal › Article › peer-review

ID: 269483823

Top